Adicet Bio (ACET) vs Gossamer Bio (GOSS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adicet Bio (ACET) has outperformed Gossamer Bio (GOSS) over the past year, losing 61.4% versus a loss of 94.9%. Over five years, ACET leads with a -95.5% price change compared with -99.1% for GOSS. Gossamer Bio is the larger company by market cap ($60.4 million vs $53.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | GOSS |
|---|---|---|
| Share price | $5.74 | $9.88 |
| Market cap | $53.73M | $60.43M |
| 1-day change | -7.12% | -2.95% |
| YTD return | -31.83% | -96.02% |
| 1-year return | -61.38% | -94.90% |
| 5-year return | -95.54% | -99.12% |
| EPS (TTM) | $-10.42 | $-52.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $309.60 |
| 52-week low | $5.55 | $9.12 |
| Distance from 52-week high | -67.09% | -96.81% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +506.79% | +734.82% |
| Average volume | 172.38K | 377.00K |
| Shares outstanding | 9.36M | 6.12M |
| Employees | 102 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACET has outperformed GOSS by 33.5 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
ACET vs GOSS FAQ
Which is bigger, Adicet Bio or Gossamer Bio?
Gossamer Bio (GOSS) is larger, with a market capitalization of $60.43M compared with $53.73M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or GOSS?
ACET returned -61.38% over the past 12 months, compared with -94.90% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Gossamer Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.